Does an Inconclusive Biopsy Mean No Cancer?

An inconclusive biopsy does not rule out cancer. It means the tissue sample collected was not sufficient, in quality or quantity, for a pathologist to make a definitive diagnosis. Depending on the organ involved and the specific type of abnormality seen under the microscope, the chance that cancer is eventually found on follow-up ranges from roughly one in five to nearly one in two. That wide range is part of what makes inconclusive results so unsettling, and it’s why doctors almost always recommend further evaluation rather than watchful waiting alone.

What “Inconclusive” Actually Means on a Pathology Report

Pathology reports don’t always land on a clean “benign” or “malignant.” Between those poles sits a range of in-between findings, and the language varies by organ. A thyroid biopsy might come back as “atypia of undetermined significance.” A breast biopsy might be labeled a “B3 lesion” or “atypical ductal hyperplasia.” A prostate biopsy could read “atypical small acinar proliferation” (ASAP). These aren’t code for “probably fine.” They’re the pathologist’s way of saying the cells look abnormal but not abnormal enough to diagnose cancer outright, or that the sample itself was too small, crushed, or poorly preserved to interpret.

Sometimes the word “nondiagnostic” appears, which is even more frustrating. That typically means the needle didn’t capture enough of the right tissue to say anything meaningful at all. It’s not a judgment about whether cancer is present. It’s an admission that the sample failed before the analysis could begin.

Why Biopsies Come Back Inconclusive

The single biggest factor is who performs the procedure. A study of over 1,900 fine-needle aspiration biopsies found that when pathologists performed the procedure themselves, the inadequacy rate was about 8 percent. When non-pathologist specialists did it, that rate jumped to roughly 25 percent.¹ The explanation is straightforward: pathologists can evaluate smears in real time and immediately take another pass if the first one looks thin. Other clinicians send the sample off and hope for the best.

Beyond operator skill, several technical and anatomical factors matter. The tumor’s location plays a role. Pancreatic lesions in the body or tail of the organ, for instance, are more accessible than those in the head, and the needle type, gauge, number of passes, and suction technique all independently affect whether a repeat procedure produces a clear answer.² Sampling error is another contributor. In a study of chondrosarcoma (a bone cancer), biopsy sampling errors occurred in about 15 percent of cases.³ Tumors are not homogeneous masses. A needle can land in a patch of dead tissue, inflammation, or normal cells right next to malignant ones and come back clean.

Small lesions and deep-seated tumors compound the problem. If the target is a centimeter across and sits behind ribs or bowel, even image-guided needles occasionally miss. And some cancers grow in a diffuse, scattered pattern rather than forming a solid lump, making it harder to capture a representative sample no matter how skilled the operator is.

How Often Cancer Shows Up After an Inconclusive Breast Biopsy

Breast biopsies are probably the setting where inconclusive results generate the most anxiety, partly because screening catches so many borderline findings. A B3 lesion on core biopsy means the tissue shows something unusual but not outright cancer. Across a large Australian screening program, the overall upgrade rate from B3 to malignancy at surgical excision was about 26 percent. When the B3 lesion contained atypia, that figure rose to roughly 35 percent. Without atypia, it dropped to about 14 percent.⁴ A separate European cohort found a similar overall upgrade rate of about 29 percent.⁵

A specific diagnosis that straddles the line is atypical ductal hyperplasia (ADH). This finding on a needle biopsy upgrades to cancer after surgical excision anywhere from about 7 to 46 percent of the time, depending on the study and the patient population.⁶ That is an enormous range, and it reflects how much individual factors like the size of the lesion, the imaging appearance, and the number of atypical foci found on the biopsy influence each person’s risk. It also explains why most guidelines recommend excisional biopsy for ADH rather than surveillance alone.

For another common borderline breast finding, lobular in-situ neoplasia (LCIS), the decision is more nuanced. Some women with limited LCIS found incidentally during screening can safely be monitored, but those who have extensive disease or whose biopsy was prompted by a suspicious imaging finding are typically advised to have an excision.⁷

Thyroid Nodules and the Gray Zone

Thyroid fine-needle aspiration results are reported using the Bethesda System, which has six categories. Categories I (nondiagnostic) and III (atypia of undetermined significance) are the main sources of inconclusive results, and together they account for a sizable share of all thyroid biopsies. The estimated malignancy risk for Bethesda III nodules has been debated for years, but a recent study that subclassified these nodules by the type of atypia found malignancy in about 42 percent of cases that went to surgery. When the atypia was nuclear (meaning the cells’ nuclei looked abnormal), the cancer rate climbed to roughly 68 percent. Architectural atypia, where the arrangement of cells was unusual but the nuclei looked more normal, carried a lower rate of about 32 percent.⁸

These numbers should be interpreted with some caution. They come from the subset of patients whose nodules were deemed suspicious enough to operate on, so they overrepresent higher-risk cases. Still, the data make clear that “indeterminate” on a thyroid biopsy is not remotely the same as “benign.” When a pathologist cannot reach a clear answer, one option is to send the original slides to a specialist for a second-opinion diagnosis. A review of over 7,000 thyroid aspirates found that about 15 percent were originally called indeterminate, and a second-opinion review resolved roughly 43 percent of those to a definitive diagnosis.⁹

Prostate and Pancreatic Findings

In the prostate, the most common inconclusive diagnosis is atypical small acinar proliferation, or ASAP. It tells you the pathologist saw small clusters of glands that look suspicious but doesn’t have enough tissue to call them cancerous. This finding carries a high rate of cancer detection on repeat biopsy. In a study of 102 men with an initial ASAP diagnosis, about 45 percent were eventually diagnosed with prostate cancer after repeat biopsy, and roughly 20 percent had clinically significant disease.¹⁰ The vast majority of those cancers were found on the second biopsy, with only a handful requiring a third or fourth attempt. This is why urologists treat ASAP as a near-mandate for repeat biopsy, typically within a year.

Pancreatic masses present a different challenge. They are hard to reach, often surrounded by inflammation from pancreatitis, and the tissue is fragile. When a first endoscopic ultrasound-guided biopsy comes back inconclusive, repeat procedures with optimized technique (more needle passes, a larger-gauge needle, and suction) significantly improve the chances of getting a clear answer.² In one study, a repeat procedure yielded a pathological diagnosis in about 63 percent of patients whose first biopsy had been inconclusive. The takeaway is that technical refinements on the second attempt matter as much as the decision to try again.

Repeat Biopsy, Core Needle, or Surgical Excision

When a biopsy is inconclusive, the default next step in most settings is to repeat it. But repeating the same technique sometimes just produces the same ambiguous result. For thyroid nodules, a meta-analysis comparing core-needle biopsy (CNB) with repeat fine-needle aspiration found that core-needle biopsy was far less likely to return another inconclusive result. The rate of nondiagnostic findings dropped dramatically with CNB, and sensitivity for detecting cancer was about 75 percent for core needle versus roughly 57 percent for repeat fine-needle aspiration.¹¹ Both methods were highly specific, meaning a “malignant” result from either one was almost certainly correct. The difference was in how often each method could actually reach a conclusion at all.

For soft-tissue masses, repeat ultrasound-guided biopsy after an inconclusive first attempt yields a diagnosis about 48 percent of the time.¹² That is helpful but far from certain, and it means about half of patients will still need surgical biopsy or excision to get an answer. In prostate cancer, MRI-targeted fusion biopsy on a second round identified clinically significant cancer in about 21 percent of men whose first targeted biopsy had been negative.¹³

One underappreciated safeguard is imaging-pathology correlation, particularly in breast biopsies. After every image-guided biopsy, the radiologist and pathologist should compare notes: does the pathology result make sense given what the imaging showed? If a mass looks highly suspicious on ultrasound or mammography but the biopsy comes back benign, that discordance is a red flag that the needle may have missed the target. A systematic review found that these discordant benign results are uncommon in unselected biopsy populations but carry a meaningful risk of upgrade to cancer, which is why structured correlation and prompt follow-up (repeat biopsy or excision) are standard practice.¹⁴

When Blood Tests Can Help Fill the Gap

Liquid biopsy, which detects fragments of tumor DNA circulating in the bloodstream, is increasingly used as a complement to tissue biopsy in advanced cancers, especially lung cancer. But its usefulness depends heavily on how much tumor DNA is actually present in the blood sample. A study of over 500 lung cancer patients whose liquid biopsy found no targetable mutations revealed that 37 percent of them did have a driver mutation when tissue-based profiling was performed. The common thread: virtually all of those missed cases had very low circulating tumor DNA levels (below 1 percent tumor fraction). When tumor fraction was at or above 1 percent, the agreement between liquid and tissue biopsy for identifying driver mutations was about 98 percent.¹⁵

This means a “negative” liquid biopsy in the setting of a known or suspected cancer is not necessarily trustworthy unless the lab confirms that enough tumor DNA was present to detect a mutation if one existed. When tumor shedding is low, as it often is in early-stage disease or certain tumor types, a tissue biopsy remains essential. Liquid biopsy is most useful as a fallback when tissue is hard to obtain or when you need rapid results to guide treatment in advanced disease. It is not a replacement for an inconclusive tissue biopsy in a diagnostic workup.

Advanced Pathology Techniques for Difficult Cases

When a small biopsy sample is ambiguous under the microscope, pathologists can sometimes settle the question by adding specialized stains or molecular tests to the same tissue. Immunohistochemistry, which uses antibodies to highlight specific proteins in cells, is one common approach. In brain tumors, for instance, immunostaining for a particular mutation (IDH1-R132H) proved more sensitive than genetic sequencing in tiny biopsy specimens, because the stain could pick up the mutation in just a few tumor cells mixed in with normal brain tissue.¹⁶ However, these specialized tests have their own limitations. Background staining can create false positives, and when the tumor is scattered diffusely through normal tissue, even immunohistochemistry can struggle.

Molecular profiling panels, which analyze dozens or hundreds of genes at once, are increasingly used for inconclusive biopsies in thyroid, lung, and other cancers. In thyroid nodules, commercially available gene expression classifiers can reclassify a Bethesda III or IV nodule as likely benign or suspicious, helping patients avoid unnecessary surgery. These tests work best when there is enough tissue left over from the original biopsy to run them, which is one reason pathologists try to conserve material from the initial sample.

Children Face Different Diagnostic Challenges

Pediatric tumors behave differently from adult cancers, and the biopsy challenges reflect that. A prospective study comparing core-needle biopsy to open wedge biopsy in children with solid abdominal tumors found a striking difference. Open surgical biopsy was considered fully diagnostic by both reviewing pathologists in 93 percent of cases, while core-needle biopsy was fully diagnostic in only 29 percent. In nearly a third of children, core-needle biopsy was deemed nondiagnostic by both pathologists.¹⁷ The tumors that were hardest to diagnose by needle included neuroblastoma, hepatoblastoma, and ganglioneuroblastoma, all of which have complex tissue architecture that small needle cores may not capture adequately.

This doesn’t mean all children with suspicious tumors need open surgery for diagnosis, but it highlights that the bar for what constitutes an adequate sample can be higher in pediatric oncology. Treatment protocols for childhood cancers often require precise tumor subtyping and molecular characterization that demand more tissue than adult protocols do.

The Psychological Toll of Waiting in Limbo

An inconclusive result creates a specific kind of distress that differs from a clear positive or negative. You might expect that an ambiguous result would cause less anxiety than a cancer diagnosis, but the research tells a more complicated story. A review of studies on people who received inconclusive genetic test results for BRCA1/2 mutations found that most studies did not detect a significant difference in overall psychological distress compared to those who received definitive positive or negative results. However, some individuals with inconclusive results showed elevated distress, particularly around physical symptoms. And unlike people who receive a negative result, whose anxiety tends to decrease over time, those with inconclusive results did not show that natural decline in distress in the months following their result.¹⁸

While this research focused on genetic testing rather than tissue biopsy, the psychological dynamics are analogous. Uncertainty is its own burden. People can adjust to bad news, but they struggle to adjust to no news. If you’re in this position, pressing your care team for a clear timeline and concrete next steps, rather than open-ended “we’ll watch and see” language, can help restore a sense of control even before the diagnostic picture resolves.

When Imaging and Biopsy Disagree

One scenario that deserves specific attention is when the biopsy says “benign” but the imaging looks suspicious. This is called imaging-pathology discordance, and it is not the same as an inconclusive biopsy, though patients sometimes conflate the two. Discordance matters because a benign biopsy result in the setting of a suspicious-looking mass could mean the needle sampled the wrong part of the lesion entirely. Radiologic-pathologic correlation, the formal process of comparing biopsy findings against imaging, is considered critical for catching these sampling errors and preventing delayed diagnoses.¹⁹

If your doctor tells you that your biopsy and imaging are discordant, treat it with the same seriousness as an explicitly inconclusive result. The standard recommendation in breast imaging, and increasingly in other fields, is to proceed with either repeat biopsy or surgical excision rather than reassurance alone.¹⁴ If your provider suggests monitoring without explaining why discordance is not a concern in your specific case, it is reasonable to ask for clarification or request a second opinion.